What is STERIS's life sciences: — R&D?

STERIS (STE) reported life sciences: — R&D of $2.8M in Q4 2025.

What does life sciences: — R&D mean?

This metric tracks the investment in innovation, product development, and engineering specifically dedicated to the Life Sciences segment. It highlights the company's commitment to advancing sterilization technology and meeting evolving regulatory standards in the biopharma industry.

STERIS STE Life Sciences: — R&D

Other segment segments

Healthcare Segment

$25.3M+6.8%

AST

$800K-27.3%

Similar metrics at other companies

RVTYLife Sciences — Segment research and development expenses

$31.62M+11.9%

CYRXLife Sciences Services — Research And Development Expense Excluding Compensation And Depreciation And Amortization

$202K-79.5%

ASHLife Sciences — Research And Development Expense

$3M-25.0%

CYRXLife Sciences Products — Research And Development Expense Excluding Compensation And Depreciation And Amortization

$513K+24.5%

TMOLife Sciences Solutions — Research and development expenses

$131M-5.8%

GLW

GLWLife Sciences and Emerging Growth Businesses — Research, development and engineering expenses

$28M-6.7%

Other financials

Income statement

See full

Revenue$1.6B+7.3%

Gross profit$697.2M+8.8%

Operating income$316.8M+46.6%

Net income$220.2M+51.2%

EPS (diluted)$2.24+52.4%

Balance sheet

See full

Cash & equivalents$439.6M+156%

Total debt$2.1B-10.3%

Total equity$7.2B+8.8%

Total assets$10.7B+5.8%

Cash flow

See full

Operating cash flow$335.4M+28.6%

CapEx$90.2M+27.2%

Free cash flow$245.2M+29.1%

Valuation

See full

Market cap$20.52B-9.4%

Enterprise value$22.17B-8.8%

P/E26.2×-8.8×

P/S3.5×-0.6×

Profitability

See full

Gross margin44.2%+0.2pp

Operating margin18.6%+2.7pp

Net margin13.2%+1.9pp

FCF margin16.4%+2.1pp

Returns & leverage

See full

Return on equity11.3%+1.8pp

Debt / equity0.3×-0.1×

Current ratio2.1×+0.1×

Where this comes from

Reported directly by STERIS in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: STERIS’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about STERIS's life sciences: — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is STERIS's life sciences: — R&D?: STERIS (STE) reported life sciences: — R&D of $2.8M in Q4 2025.
What does life sciences: — R&D mean?: This metric tracks the investment in innovation, product development, and engineering specifically dedicated to the Life Sciences segment. It highlights the company's commitment to advancing sterilization technology and meeting evolving regulatory standards in the biopharma industry.